WEC
EBS icon

Winslow Evans & Crocker’s Emergent Biosolutions EBS Stock Holding History

Winslow Evans & Crocker’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$19K Sell
214
-936
-81% -$85.9K ﹤0.01% 797
2020
Q3 		$119K Hold
1,150
– – 0.03% 336
2020
Q2 		$91K Buy
+1,150
New +$85.7K 0.02% 373
2019
Q2 		– Sell
-46
Closed -$4K – 1194
2019
Q1 		$4K Buy
+46
New +$2.71K ﹤0.01% 1001

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Winslow Evans & Crocker's EBS Position: Q4 2020 in Review

Winslow Evans & Crocker reduced its Emergent Biosolutions (EBS) stake by 81% in Q4 2020, selling an estimated $85.9K and leaving 214 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #797.

Winslow Evans & Crocker first reported a position in EBS in Q1 2019 and has held it in 4 quarters since. The position peaked at $119K in Q3 2020. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

  • Winslow Evans & Crocker held 214 shares of Emergent Biosolutions worth $19K as of Q4 2020.
  • Winslow Evans & Crocker sold 936 Emergent Biosolutions shares in Q4 2020, an estimated $85.9K.
  • Emergent Biosolutions made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #797 holding.
  • Winslow Evans & Crocker first reported a position in Emergent Biosolutions in Q1 2019 and has held it in 4 quarters since.
  • Winslow Evans & Crocker's Emergent Biosolutions position peaked at $119K in Q3 2020.
  • 353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.